2025-10-05 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the provided data, formatted as requested.

## NTRA Stock Analysis

**Company Overview:** Natera Inc. is a genetic testing company focusing on non-invasive prenatal testing (NIPT) and cancer screening.

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 72.99%
*   **VOO Cumulative Return:** 98.77%
*   **Deviation:** -33.1
*   **Relative Deviation:** 21.0

**Analysis:** NTRA has underperformed the S&P 500 over the analyzed period. The relative deviation of 21.0 suggests that NTRA's current underperformance is closer to its historical lows compared to VOO.

**Historical Performance (CAGR, MDD, Alpha, Beta):**

| Year       |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|:-----------|-------:|------:|--------:|-------:|---------:|
| 2015-2017  |   -10  |  70.1 |   -34   |   -0.2 |      1.2 |
| 2016-2018  |    22  |  80   |     6   |    0.1 |      1.9 |
| 2017-2019  |    50  |  80   |    28   |    1   |      4.6 |
| 2018-2020  |   186  |  80.5 |   163   |    1.1 |     13.7 |
| 2019-2021  |    96  |  80.5 |    49   |    1.6 |     12.8 |
| 2020-2022  |   -77  |  80.5 |   -76   |    0.1 |      5.5 |
| 2021-2023  |   -194 |  76.6 |  -195   |   -1.1 |      8.6 |
| 2022-2024  |     8  |  76.6 |   -13   |   -1.2 |     21.7 |
| 2023-2025  |   100  |  76.6 |    37   |    0.1 |     23   |

**Analysis:**

*   **CAGR:** Highly variable, ranging from -194% to 186%, indicating significant volatility. Recent years show a strong recovery in 2023-2025.
*   **MDD:** High Maximum Drawdowns consistently above 70%, reflecting the risk associated with this stock.
*   **Alpha:** NTRA's alpha is highly variable and often negative, suggesting it frequently underperforms relative to its risk.
*   **Beta:** Beta values fluctuate, indicating the stock's correlation with the market varies. The negative betas in recent periods may indicate the stock has been moving counter to the market.
*   **Cap(B):** Market capitalization has generally increased over time.

### 2. Recent Stock Price Movement

*   **Current Price:** 167.35
*   **Previous Close:** 160.21
*   **Change:** 4.46
*   **5-day Moving Average:** 162.13
*   **20-day Moving Average:** 169.37
*   **60-day Moving Average:** 158.00

**Analysis:** The stock is trading above its 5-day and 60-day moving averages but below its 20-day moving average. The significant price increase since the previous close suggests a positive short-term momentum.

### 3. Technical Indicators and Expected Return

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 43.87 (Neutral)
*   **PPO:** -0.93 (Bearish)
*   **Hybrid Signal:** Buy 100% of cash (6 shares - Very Safe)
*   **Delta_Previous_Relative_Divergence:** -2.6 (Short-term decrease)
*   **Expected Return:** -179.7%

**Analysis:**

*   The MRI suggests a high investment recommendation, indicating a favorable risk-reward balance according to this metric.
*   The RSI is neutral, not indicating overbought or oversold conditions.
*   The negative PPO suggests a bearish trend.
*   The negative change in relative divergence indicates recent underperformance.
*   The significantly negative expected return suggests that, from the current position, the stock is expected to underperform the S\&P 500 over the long term if a dollar-cost averaging strategy is used.
*   The large `change` value (4.46) indicates recent volatility and a potential positive swing in momentum.

### 4. Recent News & Events

*   **October 1, 2025:** Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
*   **October 1, 2025:** Exploring 3 High Growth Tech Stocks In The US Market
*   **September 30, 2025:** Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
*   **September 29, 2025:** Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
*   **September 29, 2025:** 2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds
*   **September 25, 2025:** Stocks making big moves yesterday: Acadia Healthcare, Tesla, THOR Industries, Natera, and P10

**Analysis:** The recent news is generally positive, focusing on advancements in Natera's testing capabilities and clinical trial progress. However, the "Stocks making big moves yesterday" headline suggests volatility.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.53)
*   **Opinions:** 19
*   **Target Price:** Avg: 193.21 / High: 235.00 / Low: 37.00

**Analysis:** Analysts generally have a positive outlook on the stock, with a "Buy" consensus and a significant average target price above the current price. The wide range in target prices, however, indicates considerable uncertainty.

### 5. Recent Earnings Analysis

| 날짜       |   EPS | 매출      |
|:-----------|------:|:----------|
| 2025-08-08 | -0.74 | 0.55 B$   |
| 2025-05-09 | -0.5  | 0.50 B$   |
| 2024-11-12 | -0.26 | 0.44 B$   |
| 2024-08-09 | -0.3  | 0.41 B$   |
| 2025-08-08 | -0.3  | 0.41 B$   |

**Analysis:**

*   The company is not yet profitable, as indicated by the negative EPS values.
*   Revenue has been generally increasing over the past few quarters.

### 6. Financial Information

| Quarter    |   Revenue |   Profit Margin |
|:-----------|----------:|----------------:|
| 2025-06-30 |      0.55B |           63.41 |
| 2025-03-31 |      0.50B |           63.12 |
| 2024-12-31 |      0.48B |           62.94 |
| 2024-09-30 |      0.44B |           61.79 |
| 2024-06-30 |      0.41B |           58.83 |

| Quarter    |   Equity |     ROE |
|:-----------|---------:|--------:|
| 2025-06-30 |     1.25B |   -8.1  |
| 2025-03-31 |     1.24B |   -5.4  |
| 2024-12-31 |     1.20B |   -4.5  |
| 2024-09-30 |     0.88B |   -3.6  |
| 2024-06-30 |     0.84B |   -4.48 |

**Analysis:**

*   **Revenue:** Shows a consistent growth trend over the last five quarters.
*   **Profit Margin:** Remains strong, consistently above 58%.
*   **Equity:** Increasing, indicating a strengthening balance sheet.
*   **ROE:** Negative, reflecting the company's current unprofitability. However, the trend is improving.

### 7. Overall Assessment

Natera (NTRA) presents a mixed picture. While the company shows strong revenue growth, high profit margins, and positive advancements in its core business (as highlighted by recent news), it is currently unprofitable and has underperformed the broader market. Analyst ratings are generally positive, but technical indicators are mixed, and the expected return is notably negative.

**In Summary:**

*   **Strengths:** Strong revenue growth, high profit margins, innovative products, positive analyst ratings.
*   **Weaknesses:** Current unprofitability, historical underperformance vs. S&P 500, high volatility.
*   **Considerations:** The stock is potentially a high-risk, high-reward investment. The company's growth trajectory depends on successful commercialization of its testing services. The negative expected return suggests caution. Monitor upcoming earnings and further developments in its clinical trials.
